Live Chat

Los Contratos por diferencia («CFD») son instrumentos complejos que comportan un riesgo elevado de pérdidas rápidas debido al apalancamiento. El 76,3% de las cuentas de inversores particulares pierde dinero al operar CFD con este proveedor. Debe considerar si comprende el funcionamiento de los CFD y si puede permitirse asumir un riesgo elevado de perder su dinero.

Close

Amgen gráfico en tiempo real

Perspectivas

Weekly Search
Weekly
Daily
date Cerrar change Cambio del % Apertura Alto Bajo

Markets.com news

bitcoin rising
Alec Malloy 2024 Aug 19, 16:05

Test News Spanish Article Only

BoE Acciones
French election results to drive European markets
markets.com Support Team 2024 Jul 04, 21:00

Adelanto semanal: Los resultados de las elecciones francesas clave para los mercados europeos

Forex Índices
Macron calls snap election, riles markets
markets.com Support Team 2024 Jun 29, 21:00

Adelanto semanal: ¿Francia desencadenará la próxima crisis del euro?

CPI
Businessman pointing hologram online banking icon.
markets.com Support Team 2024 Jun 20, 16:00

Adelanto semanal: Muchos datos e información sobre la inflación

Forex Índices

Información

Spread

1.72

Spread (%)

0.6479 %

Apalancamiento

1:5

Interés a un día (Compra)

-0.0597 %

Interés a un día (Venta)

-0.0292 %

Divisa

USD

Horarios de los mercados

Markets closed

Martes

14:31 - 20:59

Lunes

14:31-20:59

Miércoles

14:31-20:59

Jueves

14:31-20:59

Viernes

14:31-20:59

Estado de resultados

Apertura

---

Cierre anterior

---

Máximo/mínimo de 52 semanas

--- – ---

Capitalización de mercado

141908705280

Acciones en circulación

537532992

Fecha de ganancias (próxima)

1999-11-22

instr__dividend_date

2025-03-07

instr__ex_dividend_date

2025-02-14

instr__forward_annual_dividend_rate

9.52

instr__forward_annual_dividend_yield

0.0361

GPA

7.84

Acciones en circulación

Amgen Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Conoce más sobre este instrumento

Activo
Vender
Comprar
Cambio del %
Instrumentos relacionados
Trustpilot
Live Chat